OMS906

Phase 2Biologic

OOmeros Corporation

OMS906 is one of 65 biologic programs targeting Paroxysmal Nocturnal Hemoglobinuria. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Paroxysmal Nocturnal HemoglobinuriaActive, not recruiting

Safety and EfficacyRecruiting

Paroxysmal Nocturnal HemoglobinuriaPhase 2

Active, not recruiting

Safety and EfficacyPhase 2

Recruiting

Competition

Competitive Landscape

149 competitors in Safety and Efficacy

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

8 2

Opdivo

Bristol-Myers Squibb

Phase 3

7 3

Avastin

Roche

Phase 3

3 4

Humira

Novartis

Phase 3

3 5

BEYFORTUS

Sanofi

Phase 3

1 6

Oncovin

Eli Lilly

Phase 3

1 7

Neulasta

Amgen

Phase 3

1 8

Adriamycin

Pfizer

Phase 3

1 9

Cytoxan

BBaxter Healthcare Corporation

Phase 3

6 10

Rayos

RRoxane Laboratories

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Paroxysmal Nocturnal Hemoglobinuria

NCT06298955

Clinical

Trials by Indication[1]

Paroxysmal Nocturnal Hemoglobinuria3 trials

Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab

Completed·OOmeros Corporation·Phase 2·NCT05972967·12 enrolled

Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria

Unknown status·OOmeros Corporation·Phase 1·NCT05889299·10 enrolled

An Open-Label Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Active, not recruiting·OOmeros Corporation·Phase 2·NCT06298955·25 enrolled

Safety and Efficacy1 trial

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

Recruiting·OOmeros Corporation·Phase 2·NCT06209736·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for OMS906. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OMS906 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OMS906. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Omeros Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: OOmeros Corporation

OMS906

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Paroxysmal Nocturnal Hemoglobinuria3 trials

Safety and Efficacy1 trial

References

Drug Info

Quick Facts

Related News